This pipeline uses various statistical tests to identify miRs whose expression levels correlated to selected clinical features.
Testing the association between 518 miRs and 12 clinical features across 53 samples, statistically thresholded by Q value < 0.05, 2 clinical features related to at least one miRs.
-
1 miR correlated to 'HISTOLOGICAL.TYPE'.
-
HSA-MIR-552
-
4 miRs correlated to 'COMPLETENESS.OF.RESECTION'.
-
HSA-MIR-411 , HSA-MIR-758 , HSA-MIR-377 , HSA-MIR-329-1
-
No miRs correlated to 'Time to Death', 'AGE', 'NEOPLASM.DISEASESTAGE', 'PATHOLOGY.T.STAGE', 'PATHOLOGY.N.STAGE', 'PATHOLOGY.M.STAGE', 'GENDER', 'NUMBERPACKYEARSSMOKED', 'YEAROFTOBACCOSMOKINGONSET', and 'NUMBER.OF.LYMPH.NODES'.
Complete statistical result table is provided in Supplement Table 1
Table 1. Get Full Table This table shows the clinical features, statistical methods used, and the number of miRs that are significantly associated with each clinical feature at Q value < 0.05.
Clinical feature | Statistical test | Significant miRs | Associated with | Associated with | ||
---|---|---|---|---|---|---|
Time to Death | Cox regression test | N=0 | ||||
AGE | Spearman correlation test | N=0 | ||||
NEOPLASM DISEASESTAGE | ANOVA test | N=0 | ||||
PATHOLOGY T STAGE | Spearman correlation test | N=0 | ||||
PATHOLOGY N STAGE | t test | N=0 | ||||
PATHOLOGY M STAGE | ANOVA test | N=0 | ||||
GENDER | t test | N=0 | ||||
HISTOLOGICAL TYPE | ANOVA test | N=1 | ||||
NUMBERPACKYEARSSMOKED | Spearman correlation test | N=0 | ||||
YEAROFTOBACCOSMOKINGONSET | Spearman correlation test | N=0 | ||||
COMPLETENESS OF RESECTION | ANOVA test | N=4 | ||||
NUMBER OF LYMPH NODES | Spearman correlation test | N=0 |
Table S1. Basic characteristics of clinical feature: 'Time to Death'
Time to Death | Duration (Months) | 0-49.4 (median=4.9) |
censored | N = 33 | |
death | N = 17 | |
Significant markers | N = 0 |
Table S2. Basic characteristics of clinical feature: 'AGE'
AGE | Mean (SD) | 65.91 (11) |
Significant markers | N = 0 |
Table S3. Basic characteristics of clinical feature: 'NEOPLASM.DISEASESTAGE'
NEOPLASM.DISEASESTAGE | Labels | N |
STAGE IA | 2 | |
STAGE IB | 2 | |
STAGE IIA | 6 | |
STAGE IIB | 39 | |
STAGE III | 2 | |
STAGE IV | 2 | |
Significant markers | N = 0 |
Table S4. Basic characteristics of clinical feature: 'PATHOLOGY.T.STAGE'
PATHOLOGY.T.STAGE | Mean (SD) | 2.91 (0.49) |
N | ||
1 | 2 | |
2 | 3 | |
3 | 46 | |
4 | 2 | |
Significant markers | N = 0 |
Table S5. Basic characteristics of clinical feature: 'PATHOLOGY.N.STAGE'
PATHOLOGY.N.STAGE | Labels | N |
class0 | 12 | |
class1 | 41 | |
Significant markers | N = 0 |
Table S6. Basic characteristics of clinical feature: 'PATHOLOGY.M.STAGE'
PATHOLOGY.M.STAGE | Labels | N |
M0 | 27 | |
M1 | 2 | |
MX | 24 | |
Significant markers | N = 0 |
Table S7. Basic characteristics of clinical feature: 'GENDER'
GENDER | Labels | N |
FEMALE | 28 | |
MALE | 25 | |
Significant markers | N = 0 |
Table S8. Basic characteristics of clinical feature: 'HISTOLOGICAL.TYPE'
HISTOLOGICAL.TYPE | Labels | N |
PANCREAS-ADENOCARCINOMA DUCTAL TYPE | 47 | |
PANCREAS-ADENOCARCINOMA-OTHER SUBTYPE | 4 | |
PANCREAS-COLLOID (MUCINOUS NON-CYSTIC) CARCINOMA | 1 | |
Significant markers | N = 1 |
Table S9. Get Full Table List of one miR differentially expressed by 'HISTOLOGICAL.TYPE'
ANOVA_P | Q | |
---|---|---|
HSA-MIR-552 | 4.275e-05 | 0.0221 |
Figure S1. Get High-res Image As an example, this figure shows the association of HSA-MIR-552 to 'HISTOLOGICAL.TYPE'. P value = 4.28e-05 with ANOVA analysis.
![](V8ex.png)
Table S10. Basic characteristics of clinical feature: 'NUMBERPACKYEARSSMOKED'
NUMBERPACKYEARSSMOKED | Mean (SD) | 24.25 (16) |
Significant markers | N = 0 |
Table S11. Basic characteristics of clinical feature: 'YEAROFTOBACCOSMOKINGONSET'
YEAROFTOBACCOSMOKINGONSET | Mean (SD) | 1971.64 (12) |
Significant markers | N = 0 |
Table S12. Basic characteristics of clinical feature: 'COMPLETENESS.OF.RESECTION'
COMPLETENESS.OF.RESECTION | Labels | N |
R0 | 28 | |
R1 | 20 | |
RX | 2 | |
Significant markers | N = 4 |
Table S13. Get Full Table List of 4 miRs differentially expressed by 'COMPLETENESS.OF.RESECTION'
ANOVA_P | Q | |
---|---|---|
HSA-MIR-411 | 9.437e-06 | 0.00489 |
HSA-MIR-758 | 4.033e-05 | 0.0208 |
HSA-MIR-377 | 6.618e-05 | 0.0341 |
HSA-MIR-329-1 | 7.196e-05 | 0.0371 |
Figure S2. Get High-res Image As an example, this figure shows the association of HSA-MIR-411 to 'COMPLETENESS.OF.RESECTION'. P value = 9.44e-06 with ANOVA analysis.
![](V11ex.png)
-
Expresson data file = PAAD-TP.miRseq_RPKM_log2.txt
-
Clinical data file = PAAD-TP.merged_data.txt
-
Number of patients = 53
-
Number of miRs = 518
-
Number of clinical features = 12
For survival clinical features, Wald's test in univariate Cox regression analysis with proportional hazards model (Andersen and Gill 1982) was used to estimate the P values using the 'coxph' function in R. Kaplan-Meier survival curves were plot using the four quartile subgroups of patients based on expression levels
For continuous numerical clinical features, Spearman's rank correlation coefficients (Spearman 1904) and two-tailed P values were estimated using 'cor.test' function in R
For multi-class clinical features (ordinal or nominal), one-way analysis of variance (Howell 2002) was applied to compare the log2-expression levels between different clinical classes using 'anova' function in R
For two-class clinical features, two-tailed Student's t test with unequal variance (Lehmann and Romano 2005) was applied to compare the log2-expression levels between the two clinical classes using 't.test' function in R
For multiple hypothesis correction, Q value is the False Discovery Rate (FDR) analogue of the P value (Benjamini and Hochberg 1995), defined as the minimum FDR at which the test may be called significant. We used the 'Benjamini and Hochberg' method of 'p.adjust' function in R to convert P values into Q values.
In addition to the links below, the full results of the analysis summarized in this report can also be downloaded programmatically using firehose_get, or interactively from either the Broad GDAC website or TCGA Data Coordination Center Portal.